Jürgen K. Rockstroh mainly investigates Internal medicine, Immunology, Viral load, Hepatitis C and Acquired immunodeficiency syndrome. His Internal medicine study integrates concerns from other disciplines, such as Gastroenterology and Surgery. His research integrates issues of Liver disease, Epidemiology and Disease in his study of Immunology.
Clinical trial and Pharmacotherapy is closely connected to Integrase inhibitor in his research, which is encompassed under the umbrella topic of Viral load. His Hepatitis C research entails a greater understanding of Virology. Jürgen K. Rockstroh has included themes like Odds ratio, Hepatitis B, Stigma, Cohort study and Mental health in his Acquired immunodeficiency syndrome study.
His primary scientific interests are in Internal medicine, Immunology, Virology, Hepatitis C and Hepatitis C virus. The study incorporates disciplines such as Gastroenterology, Ribavirin, Viral load and Coinfection in addition to Internal medicine. His work in Gastroenterology covers topics such as Regimen which are related to areas like Emtricitabine.
His Immunology study frequently draws connections to adjacent fields such as Acquired immunodeficiency syndrome. His Hepatitis C course of study focuses on Cohort and Cohort study. His studies deal with areas such as Fibrosis and Men who have sex with men as well as Hepatitis C virus.
His scientific interests lie mostly in Internal medicine, Hepatitis C virus, Gastroenterology, Virology and Hepatitis C. His Internal medicine study integrates concerns from other disciplines, such as Ribavirin, Men who have sex with men, Tenofovir alafenamide and Viral load. His Viral load study contributes to a more complete understanding of Immunology.
His work carried out in the field of Hepatitis C virus brings together such families of science as Fibrosis and Liver disease. Jürgen K. Rockstroh has included themes like Placebo and Fatty liver in his Gastroenterology study. Jürgen K. Rockstroh studied Hepatitis C and Transmission that intersect with Antiretroviral therapy.
Jürgen K. Rockstroh spends much of his time researching Internal medicine, Gastroenterology, Hepatitis C, Virology and Regimen. Specifically, his work in Internal medicine is concerned with the study of Adverse effect. The various areas that Jürgen K. Rockstroh examines in his Hepatitis C study include Chronic infection, Ribavirin, Hepatitis C virus and Public health.
His work deals with themes such as Ritonavir and Hepacivirus, which intersect with Ribavirin. The study incorporates disciplines such as Dolutegravir, Lamivudine and Randomized controlled trial in addition to Regimen. His research on Hepatocellular carcinoma also deals with topics like
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial
Edwin DeJesus;Jürgen K. Rockstroh;Keith Henry;Jean Michel Molina.
The Lancet (2012)
Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel.
Vincent Soriano;Mark Sulkowski;Colm Bergin;Angelos Hatzakis.
AIDS (2002)
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study
Alison J Rodger;Valentina Cambiano;Tina Bruun;Pietro Vernazza.
The Lancet (2019)
Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): A non-randomised, open-label trial
Jürgen K. Rockstroh;Mark Nelson;Christine Katlama;Jay Lalezari.
The Lancet HIV (2015)
Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial
Jan van Lunzen;Franco Maggiolo;José R Arribas;Aza Rakhmanova.
Lancet Infectious Diseases (2012)
Selective Escape from CD8+ T-Cell Responses Represents a Major Driving Force of Human Immunodeficiency Virus Type 1 (HIV-1) Sequence Diversity and Reveals Constraints on HIV-1 Evolution
Todd M. Allen;Marcus Altfeld;Shaun C. Geer;Elizabeth T. Kalife.
Journal of Virology (2005)
Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study.
Luz Martín-Carbonero;Yves Benhamou;Massimo Puoti;Juan Berenguer.
Clinical Infectious Diseases (2004)
Variant of hepatitis B virus with primary resistance to adefovir
Oliver Schildgen;Hueseyin Sirma;Anneke Funk;Cynthia Olotu.
The New England Journal of Medicine (2006)
Care of patients with hepatitis C and HIV co-infection.
Vincent Soriano;Massimo Puoti;Mark Sulkowski;Stefan Mauss.
AIDS (2004)
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials
Roy T. Steigbigel;David A. Cooper;Hedy Teppler;Joseph J. Eron.
Clinical Infectious Diseases (2010)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
University of Bonn
University of Bonn
Rigshospitalet
University College London
University of Cologne
Hospital Universitario La Paz
University Hospital Bonn
Université Paris Cité
University of Barcelona
University of Amsterdam
University of Illinois at Urbana-Champaign
Southern University of Science and Technology
Sony (Japan)
Chinese Academy of Sciences
Oak Ridge National Laboratory
Oslo University Hospital
Zoological Society of London
North Carolina State University
University of Turin
Mayo Clinic
University of Geneva
University of Copenhagen
Technical University of Munich
Mayo Clinic
Purdue University West Lafayette
University of Chicago